Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Abemaciclib and Letrozole in ER+ Rare Ovarian Cancer
NCT05872204Phase 2Recruiting
- Sponsor
- UZ Leuven
- Start
- Nov 2023
- Primary completion
- Jan 2028
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 2, open-label, single-arm trial of abemaciclib in ovarian cancer, sponsored by UZ Leuven. Primary endpoint: Overall Response Rate at 3 years. Started Nov 2023; status: recruiting.
02
Drugs
abemaciclib
03
Conditions
ovarian cancer
Beyond the preview
Go deeper on NCT05872204.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05872204.